While significant strides have been made in understanding PI3K signaling in lung cancer, addressing the existing research gaps through targeted investigations, novel inhibitor development, combination therapies, and personalized medicine approaches will be pivotal in advancing PI3K-targeted therapies from modest clinical efficacy to meaningful patient outcomes. Here, PIK3CA is linked to lung cancer.